NLRP6 and metabolic disease: This paper showed that the NLRP6 and NLRP3 inflammasomes negatively regulate MAFLD/NASH progression and metabolic syndrome by modulating the gut microbiota, highlighting the central role of the microbiota in the pathogenesis of systemic auto-inflammation and metabolic disorders.